| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BOYER ANDREW S | Executive Vice President | C/O AMNEAL PHARMACEUTICALS, INC., BRIDGEWATER | /s/ Denis Butkovic, Attorney-in-Fact | 22 Aug 2025 | 0001239546 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMRX | Class A Common Stock | Options Exercise | $481,250 | +175,000 | +68% | $2.75 | 431,670 | 20 Aug 2025 | Direct | |
| transaction | AMRX | Class A Common Stock | Sale | $2,619,309 | -279,244 | -65% | $9.38 | 152,426 | 20 Aug 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AMRX | Stock Option | Options Exercise | $0 | -175,000 | -64% | $0.000000 | 97,480 | 20 Aug 2025 | Class A Common Stock | 175,000 | $2.75 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote. |
| F2 | These options are fully vested. |